Celgene, Novartis Resolve ADHD Patent Suits

Law360, New York (March 8, 2010, 2:24 PM EST) -- Celgene Corp. and Novartis AG have reached an agreement to settle separate patent infringement suits against KV Pharmaceutical Co. and IntelliPharmaCeutics Corp. over drugs that treat attention deficit hyperactivity disorder, the latter of which brought antitrust counterclaims against the pharmaceutical companies.

Judge Freda L. Wolfson of the U.S. District Court for the District of New Jersey signed orders Thursday that stayed both cases for 60 days in order to permit review of the settlements by certain government authorities. She also ordered that the cases be administratively...
To view the full article, register now.